莱维体痴呆症的风险因素和预测因素:系统性审查
Ahalya Ratnavel1, Francesca R Dino2, Celina Jiang3
1Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA USA.
NPJ dementia
|August 7, 2025
概括
识别勒维体痴呆症 (LBD) 的危险因素,包括帕金森病痴呆症 (PDD) 和勒维体痴呆症 (DLB),至关重要. 老年,男性性别,遗传因素和各种临床症状是经常报告的预测因素.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年病的医生 老年病的医生
背景情况:
- 莱维体痴呆症 (LBD),包括帕金森病痴呆症 (PDD) 和患有莱维体痴呆症 (DLB),代表了一种重大而具有挑战性的神经退行性疾病.
- 了解导致个人患上LBD的因素对于阐明其潜在机制和制定有针对性的治疗策略至关重要.
研究的目的:
- 系统地审查和综合从纵向研究中发现的发现,以确定莱维体痴呆症的风险因素和前兆标志物.
- 巩固有关在基线没有痴呆症的个体LBD发病前的因素的证据.
主要方法:
- 进行了全面的系统审查,搜索主要的数据库 (PubMed,Embase,Web of Science).
- 包括的研究是纵向的,评估了LBD的风险/原发性因素,招募了没有基线痴呆症的参与者,并且具有良好的/高的方法质量 (纽卡斯尔-太华尺度).
主要成果:
- 包括167项研究,确定了许多一致报告的风险因素.
- 关键预测因素包括年龄较大,男性性别,APOEε4基因型,GBA突变以及一系列临床表现,如认知变化,情绪障碍,睡眠障碍,步态异常,帕金森症和嗅觉丧失.
- 生物标志物,如MRI上的白质疾病,减少的CSF粉样蛋白β42,以及增加的CSF/血液神经丝光链也被注意到.
结论:
- 高龄,男性性别,遗传倾向以及特定的临床和生物标志物变化与患LBD的风险增加有关.
- 目前的证据库主要包括来自北美和欧洲的队列,重点是PDD,需要更广泛,更多样化的研究群体来增强可概括性和改善所有形式的LBD风险预测.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.0K
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.7K
相关概念视频
01:30Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
01:15Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:37Neural Regulation
40.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.0K
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262